Strategic Advisory Board
The board brings together distinguished leaders from clinical research, biotechnology, pharmaceutical development, intellectual property, corporate governance, finance, business development and academic medicine to provide independent strategic guidance and support EBRI's mission of translating scientific discoveries into treatments for patients living with EB.
The Advisory Board has been established in accordance with the shareholder agreement of EB Research Institute and will serve as an independent body providing strategic, scientific, and operational advice to the management team. The Board will review research strategy, assess development opportunities, contribute external perspectives on risks and challenges, and support the Institute's long-term growth and impact in rare disease research.
Martin Laimer - Chairman
Professor Martin Laimer is Professor of Dermatology and Deputy Head of the Department of Dermatology & Allergology at University Hospital Salzburg. He has worked both clinically and scientifically in the field of rare diseases, with a particular focus on epidermolysis bullosa, for more than two decades. He leads clinical research activities at EB House Austria and serves as Co-Chairman of the Executive Board of the Salzburg Centre for Rare Diseases.
Ā© Rudolf Hametner
Peter Llewellyn-Davies - Board member
Peter Llewellyn-Davies is an experienced biotechnology executive with more than forty years of international experience in company formation, financing, mergers and acquisitions, and strategic growth. He is Founder and Chief Executive Officer of Accellerate Partners and serves as President of Biotech Austria. His career includes senior leadership positions at Apeiron Biologics, invIOs and multiple listed and private biotechnology companies.
Ā© www.martinsteiger.at
Bernd Muehlenweg - Board member
Dr Bernd Muehlenweg brings more than twenty-five years of experience in biotechnology and pharmaceutical business development, strategic alliances, and corporate growth. He currently serves as Chief Business Officer and Chief Financial Officer of Cellbox Solutions and previously held senior leadership roles at Evotec, Nanobiotix, and Panoptes Pharma.
Daniela Schoegl - Board member
Dr Daniela Schoegl is an Austrian and European Patent Attorney with more than twenty-five years of experience in intellectual property protection, litigation, and innovation strategy within the biotechnology, pharmaceutical, medical device, and diagnostics sectors. She is Partner at Fabian & Schƶgl PatentanwƤlte and provides extensive expertise in protecting and commercializing scientific innovation.
Ā© Markus Nitsche Fotografie
Annemarie Weissenbacher - Board member
Professor Annemarie Weissenbacher is Rector of Paracelsus Medical Private University Salzburg. A surgeon and academic leader, she has held positions at the Medical University of Innsbruck and completed research training at the University of Oxford. Her expertise in medical research, education, and healthcare leadership contributes valuable strategic insight to the Advisory Board.
Ā© Paulina Mittermeier
Barbara Wolff-Winiski - Board member
Dr Barbara Wolff-Winiski is a translational scientist and biotechnology entrepreneur with more than thirty-five years of experience spanning academia, pharmaceutical research, and biotechnology development. She is Co-Founder, Co-CEO and Chief Scientific Officer of Akribes Biomedical and previously held senior scientific leadership positions at Novartis, where she advanced multiple therapeutic programs in dermatology and oncology.
The members of the Strategic Advisory Board together with the management of the EB Research Institute at the inauguration meeting.
From left to right: Dr Daniela Schoegl, Peter Llewellyn-Davies, Dr Hana Cernecka, Dr Bernd Muehlenweg, Prof. Annemarie Weissenbacher, Dr Barbara Wolff-Winiski, Prof. Martin Laimer
Ā© EBRI | Stefan Wagger